UASSIGNED:卒中后抑郁(PSD)是一种常见的并发症,可严重影响患者卒中后的功能恢复和生活质量。已发现各种副作用与用于PSD的药物疗法有关。临床和动物实验研究表明,中药能有效改善PSD样行为和神经功能。尚未系统分析CHM在动物模型中对PSD的功效。
UNASSIGNED:搜索了以下电子数据库,以查找截至2022年9月发布的文章:PubMed,WebofScience,Cochrane图书馆,和Embase。包括报道CHM在患有PSD的动物中的功效并且用英语撰写的研究。抑郁样行为和神经功能缺损评分被评估为疗效指标。纳入的研究使用蔗糖偏好评估抑郁样行为,开放领域,强迫游泳,和尾部悬挂试验,以及体重。使用ReviewManager版本5.4和STATA版本13.1软件包进行荟萃分析。使用具有95%置信区间的标准化平均差(SMD)来评估所有结果。进行亚组分析以探索异质性的来源。使用Egger检验和漏斗图评估潜在的发表偏倚。使用灵敏度分析来鉴定结果的稳定性。
未经评估:共14项研究,包括12只CHM,涉及442只大鼠,符合荟萃分析的纳入标准。汇总结果显示,CHM可显着缓解神经功能缺损(-1.72SMD,-2.47--0.97),并且在蔗糖偏好下有效改善大鼠的抑郁样行为(2.08SMD,1.33-2.84),开场(2.85SMD,1.88-3.83),强迫游泳(-1.83SMD,-2.23-1.44),和尾部悬挂试验(-1.35SMD,-1.94-0.76)。
UNASSIGNED:我们的结果表明,CHM可以显着改善PSD动物的抑郁样行为和神经功能。当前的结果应谨慎解释,因为仅包括动物研究。
UNASSIGNED: Poststroke depression (PSD) is a common complication that can seriously affect patients\' functional recovery and quality of life after a stroke. Various side effects have been found to be associated with the pharmacological therapies used for PSD. Studies have shown that Chinese herbal medicine (CHM) can effectively improve PSD-like behavior and neurological function in clinical and animal studies. The efficacy of CHM on PSD in animal models has not been systematically analyzed.
UNASSIGNED: The following electronic databases were searched for articles published up to September 2022: PubMed, Web of Science, the Cochrane Library, and Embase. Studies that reported the efficacy of CHM in animals with PSD and were written in English were included. Depression-like behavior and the neurological deficit score were assessed as measures of efficacy. The included studies assessed depression-like behavior using sucrose preference, open-field, forced swimming, and tail suspension tests, as well as body weight. The Review Manager version 5.4 and STATA version 13.1 software packages were used for the meta-analysis. The standardized mean difference (SMD) with 95% confidence intervals was used to assess all the outcomes. Subgroup analyses were performed to explore the sources of heterogeneity. The Egger\'s test and funnel plots were used to assess the potential publication bias. Sensitivity analyses were used to identify the stability of the results.
UNASSIGNED: A total of 14 studies, including 12 CHMs involving 442 rats, fulfilled the inclusion criteria for meta-analysis. The pooled results showed that CHM significantly alleviated neurological deficits (-1.72 SMD, -2.47- -0.97) and was efficacious in improving the depression-like behavior of rats in the sucrose preference (2.08 SMD, 1.33-2.84), open-field (2.85 SMD, 1.88-3.83), forced swimming (-1.83 SMD, -2.23-1.44), and tail suspension tests (-1.35 SMD, -1.94-0.76).
UNASSIGNED: Our results suggest that CHM could significantly improve depression-like behavior and neurological function in animals with PSD. The current results should be interpreted with caution because only animal studies were included.